Genzyme Ventures

Genzyme Ventures

Genzyme Ventures

Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years.
Follow us
MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient

$250,000,000 Post-IPO equity
Twitter

Boston Business on Twitter

The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval

The Motley Fool

Here's Why bluebird bio.'s Stock Tumbled in March

The Motley Fool

Why bluebird bio's Stock Jumped 12.9% on Wednesday

The Motley Fool

Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals

The Motley Fool

Why Bluebird Bio Inc. Plunged Today

The Motley Fool

Why bluebird bio Inc Presented a Lower Price Today

The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
Xconomy

Proteostasis Cuts Price But Heads to Nasdaq After $50M IPO

Health
The Motley Fool

Why bluebird bio Inc.'s Stock Dropped 34% in January

Stock markets
The Motley Fool

bluebird bio Inc. Takes Flight

Stock markets Health
The Motley Fool

Why Bluebird Bio Inc.'s Stock Bounced Back --

Stock markets Health
The Motley Fool

Why bluebird bio Inc's Stock Is Tanking Today --

Stock markets Health